查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930035

腦腫瘤藥物市場規模、佔有率、成長及全球產業分析：按類型、應用和地區劃分的洞察與預測（2025-2034）

Brain Tumor Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2025-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 181 Pages | 商品交期: 請詢問到貨日

價格

腦腫瘤藥物市場成長因素

全球腦腫瘤藥物市場正經歷穩定成長，主要受腦腫瘤發生率上升、診斷技術進步、藥物研發投入增加的推動。 2025年，全球市場規模為22.9億美元。預計到2026年將成長至25.5億美元，到2034年將達到52億美元，在預測期（2026-2034年）內複合年增長率（CAGR）為9.30%。

北美市場佔主導地位，2025年市佔率達43.38%。這得益於其強有力的醫療保險政策、先進的醫療基礎設施以及強大的抗癌藥物研發管線。美國腦瘤藥物市場預計將顯著成長，到 2030 年將達到 14.7 億美元。

腦瘤是由於腦內細胞不受控制地生長而形成的異常組織腫塊。它們分為原發性腦瘤和轉移性腦瘤。原發性腦瘤起源於腦部，而轉移性腦瘤則從其他器官擴散而來。原發性腦瘤佔全球確診病例的大多數。

市場驅動因素

腦瘤發生率上升

全球腦瘤發生率的上升是市場成長的主要驅動因素。生活方式的改變、吸煙、老化、輻射暴露和環境因素都導致了癌症發生率的上升。腦瘤約佔所有癌症病例的 1-2%，但死亡率很高。

根據國際癌症研究機構 (IARC) 的數據，全球腦腫瘤發生率預計將從 2024 年的 308,102 例增加到 2040 年的 415,183 例。由於診斷和治療率的提高，尤其是在北美和亞太地區，對腦腫瘤藥物的需求正在增長。

強大的在研藥物和研發投入

強大的在研藥物管線進一步支撐了市場。預計到 2025 年，將有超過 150 種腦腫瘤候選藥物進入臨床開發階段。各國政府和研究機構正積極資助腦腫瘤研究，以滿足尚未滿足的醫療需求。例如，2022 年 10 月，澳洲政府承諾撥款 400 萬美元支持腦腫瘤研究計畫。

市場趨勢

診斷技術與個人化醫療的進步

由於血腦障壁對藥物輸送的限制，腦腫瘤的早期診斷仍面臨挑戰。然而，分子診斷、液體活檢和基因生物標記分析的進步正在改善早期檢測和治療效果。

循環腫瘤DNA分析和基於血液的診斷測試等創新技術正日益受到關注。 2023年1月，Datar Cancer Genetics公司用於檢測惡性腦腫瘤的TriNetr-Glio液體活檢測試獲得了美國FDA的突破性療法認定。這些進步有望提高診斷率和藥物應用率。

新冠疫情的影響

新冠疫情期間，由於診斷和治療的延誤，腦腫瘤藥物市場受到了不利影響。根據美國疾病管制與預防中心 (CDC) 的數據，2024 年癌症發生率較 2019 年下降 11%，主要原因是篩檢率下降。主要公司也面臨供應鏈中斷和收入下降的問題。例如，羅氏公司報告稱，2024 年其阿瓦斯汀 (Avastin) 的收入下降了 29.4%。然而，隨著疫情後醫療服務的恢復，市場開始復甦。

市場區隔分析

依療法劃分

此市場細分包括化療、標靶治療、免疫療法和其他療法。

化療仍是腦腫瘤一線和輔助治療的主流，預計到2026年將佔38.49%的市場佔有率。

由於核准藥物的增加、臨床合作的進展以及精準醫療的進步，預計將標靶治療和免疫治療領域快速成長。

依適應症劃分

適應症包括膠質瘤、腦膜瘤、腦下垂體瘤等。

預計到2026年，膠質瘤領域將以41.24%的市佔率領先，這主要得益於惡性膠質瘤的高發生率以及越來越多的膠質母細胞瘤治療藥物的推出。

依通路劃分

預計到2026年，醫院藥局管道將以94.25%的市佔率佔主導地位。這是因為這些藥物需要醫院管理和保險報銷。由於門診治療的增加，零售藥局和網路藥局正在逐步擴張。

區域洞察

  • 北美：預計到 2025 年將達到 10 億美元，2026 年將達到 11 億美元，這主要得益於 FDA 的批准和完善的報銷體系。
  • 歐洲：預計到 2025 年將佔 26.83% 的市場佔有率，這主要得益於孤兒藥認定和監管支持。
  • 亞太地區：預計到 2025 年將佔 18.98% 的市場佔有率，由於公眾意識的提高和診斷技術的進步，其複合年增長率最高。
  • 拉丁美洲以及中東和非洲地區由於其完善的醫療保健基礎設施，正在穩步擴張。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 2024/2025年主要地區腦腫瘤發生率
  • 主要產業趨勢－併購、合作與收購
  • 主要地區和國家監管概覽
  • 主要公司新產品發布
  • 新冠疫情對腦腫瘤藥物市場的影響

第五章 全球腦瘤市場

腫瘤藥物市場分析、洞察與預測（2025-2034）
  • 市場分析、洞察與預測 - 按療法分類
    • 標靶治療
    • 化療
    • 免疫療法
    • 其他
  • 市場分析、洞察與預測 - 按適應症分類
    • 腦下垂體瘤
    • 腦膜瘤
    • 膠質母細胞瘤
    • 其他
  • 市場分析、洞察與預測 - 依銷售管道分類
    • 醫院藥房
    • 零售及線上藥房
  • 市場分析、洞察與預測 - 按地區分類
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東及非洲

第六章 北美腦瘤藥物市場分析、洞察與預測（2025-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲腦腫瘤藥物市場分析、洞察與預測（2025-2034）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區腦腫瘤藥物市場分析、洞察與預測（2025-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

    第九章：拉丁美洲腦瘤藥物市場分析、洞察與預測（2025-2034）

    • 依國家劃分
      • 巴西
      • 墨西哥
      • 拉丁美洲其他地區

      第十章：中東與非洲腦瘤藥物市場分析、洞察與預測（2025-2034）

      • 依國家劃分
        • 海灣合作委員會
        • 南非
        • 中東其他地區東非和非洲

      第十一章 競爭分析

      • 全球市佔率分析（2025 年）
      • 公司簡介
      • 輝瑞公司
      • 羅氏公司
      • 諾華公司
      • 默克公司
      • 安尼爾製藥股份有限公司
      • 安進公司
      • NextSource藥廠股份有限公司
      • Emcure製藥公司
Product Code: FBI105025

Growth Factors of brain tumor drugs Market

The global brain tumor drugs market is witnessing steady growth driven by the rising incidence of brain cancer, advancements in diagnosis, and increasing investment in drug development. In 2025, the global market was valued at USD 2.29 billion. It is projected to grow to USD 2.55 billion in 2026 and further reach USD 5.2 billion by 2034, registering a CAGR of 9.30% during the forecast period (2026-2034).

North America dominated the market with a 43.38% share in 2025, supported by strong reimbursement policies, advanced healthcare infrastructure, and a robust pipeline of oncology drugs. The U.S. brain tumor drugs market is expected to grow significantly, reaching USD 1.47 billion by 2030.

Brain tumors are abnormal masses of tissue caused by uncontrolled cell growth in the brain. They are classified into primary tumors, originating in the brain, and metastatic tumors, which spread from other organs. Primary tumors account for the majority of diagnosed cases globally.

Market Drivers

Rising Prevalence of Brain Cancer

The increasing prevalence of brain tumors worldwide is a major factor driving market growth. Lifestyle changes, smoking, aging populations, exposure to radiation, and environmental factors have contributed to rising cancer incidence. Brain tumors account for nearly 1-2% of total cancer cases, yet they exhibit a high mortality rate.

According to the International Agency for Research on Cancer, global brain cancer incidence is expected to rise from 308,102 cases in 2024 to 415,183 cases by 2040. Increasing diagnosis and treatment rates, particularly in North America and Asia Pacific, are boosting the demand for brain tumor drugs.

Strong Pipeline and R&D Investments

The market is further supported by a strong pipeline of investigational drugs. By 2025, more than 150 brain tumor drug candidates were under clinical development. Governments and research organizations are actively funding brain cancer research to address unmet medical needs. For instance, in October 2022, the Australian government allocated USD 4.0 million to support brain cancer research initiatives.

Market Trends

Advancements in Diagnosis and Personalized Medicine

Early diagnosis of brain tumors remains challenging due to the blood-brain barrier, which limits drug delivery. However, advancements in molecular diagnostics, liquid biopsy, and genetic biomarker analysis are improving early detection and treatment outcomes.

Innovations such as circulating tumor DNA analysis and blood-based diagnostic tests are gaining traction. In January 2023, Datar Cancer Genetics received U.S. FDA breakthrough designation for TriNetr-Glio, a liquid biopsy test for detecting malignant brain tumors. These advancements are expected to increase diagnosis rates and drug adoption.

COVID-19 Impact

The brain tumor drugs market was negatively impacted during the COVID-19 pandemic due to delayed diagnosis and treatment. According to the CDC, cancer incidence declined by 11% in 2024 compared to 2019, primarily due to reduced screenings. Major players also faced supply chain disruptions and revenue declines. For instance, F. Hoffmann-La Roche Ltd. reported a 29.4% decline in Avastin revenues in 2024. However, market recovery began as healthcare services resumed post-pandemic.

Market Segmentation Analysis

By Therapy

The market is segmented into chemotherapy, targeted therapy, immunotherapy, and others.

The chemotherapy segment dominated the market with a 38.49% share in 2026, as it remains the first-line and adjuvant treatment for brain tumors.

Targeted therapy and immunotherapy segments are expected to grow rapidly due to increasing approvals, clinical collaborations, and advancements in precision medicine.

By Indication

Based on indication, the market includes glioma, meningioma, pituitary, and others.

The glioma segment led the market with a 41.24% share in 2026, driven by the high prevalence of malignant gliomas and increasing drug launches for glioblastoma treatment.

By Distribution Channel

The hospital pharmacy segment dominated the market with a 94.25% share in 2026, as these drugs require hospital-based administration and insurance reimbursement. Retail and online pharmacies are gradually expanding with increased outpatient treatment.

Regional Insights

  • North America: Valued at USD 1.0 billion in 2025 and USD 1.1 billion in 2026, driven by FDA approvals and strong reimbursement.
  • Europe: Held 26.83% market share in 2025, supported by orphan drug designations and regulatory support.
  • Asia Pacific: Accounted for 18.98% share in 2025 and is expected to grow at the fastest CAGR due to rising awareness and improving diagnosis.
  • Latin America and Middle East & Africa are expanding steadily due to improving healthcare infrastructure.

Competitive Landscape

The market is consolidated, with leading players such as F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Merck & Co., Amgen Inc., and Amneal Pharmaceuticals LLC. Strategic initiatives including acquisitions, FDA approvals, and pipeline expansion are strengthening market competition.

Conclusion

In conclusion, the global brain tumor drugs market is poised for consistent growth, expanding from USD 2.29 billion in 2025 to USD 5.2 billion by 2034. Rising brain cancer prevalence, strong drug pipelines, advancements in diagnostics, and increasing government support are driving market expansion. Despite challenges such as high treatment costs and limited reimbursement in developing regions, continuous innovation and regulatory approvals are expected to sustain long-term market growth.

Segmentation By Therapy

  • Targeted Therapy
  • Chemotherapy
  • Immunotherapy
  • Others

By Indication

  • Pituitary
  • Meningioma
  • Glioma
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail & Online Pharmacy

By Region

  • North America (By Therapy, By Indication, By Distribution Channel, and By Country)
    • U.S. (By Indication)
    • Canada (By Indication)
  • Europe (By Therapy, By Indication, By Distribution Channel, and By Country)
    • U.K. (By Indication)
    • Germany (By Indication)
    • France (By Indication)
    • Italy (By Indication)
    • Spain (By Indication)
    • Rest of Europe (By Indication)
  • Asia Pacific (By Therapy, By Indication, By Distribution Channel, and By Country)
    • China (By Indication)
    • Japan (By Indication)
    • India (By Indication)
    • Australia (By Indication)
    • Southeast Asia (By Indication)
    • Rest of Asia Pacific (By Indication)
  • Latin America (By Therapy, By Indication, By Distribution Channel, and By Country)
    • Brazil (By Indication)
    • Mexico (By Indication)
    • Rest of Latin America (By Indication)
  • Middle East & Africa (By Therapy, By Indication, By Distribution Channel, and By Country)
    • GCC (By Indication)
    • South Africa (By Indication)
    • Rest of Middle East & Africa (By Indication)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Incidence of Brain Cancer, Key Region, 2024/2025
  • 4.2. Key Industry Developments - Mergers, Partnerships, Acquisitions
  • 4.3. Overview of the Regulatory Scenario by Key Region/Countries
  • 4.4. New Product Launches by Key Players
  • 4.5. Impact of COVID-19 on Brain Tumor Drugs Market

5. Global Brain Tumor Drugs Market Analysis, Insights and Forecast, 2025-2034

  • 5.1. Market Analysis, Insights and Forecast - By Therapy
    • 5.1.1. Targeted Therapy
    • 5.1.2. Chemotherapy
    • 5.1.3. Immunotherapy
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Indication
    • 5.2.1. Pituitary Tumors
    • 5.2.2. Meningioma
    • 5.2.3. Glioblastoma
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacy
    • 5.3.2. Retail & Online Pharmacy
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Brain Tumor Drugs Market Analysis, Insights and Forecast, 2025-2034

  • 6.1. Market Analysis, Insights and Forecast - By Therapy
    • 6.1.1. Targeted Therapy
    • 6.1.2. Chemotherapy
    • 6.1.3. Immunotherapy
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Indication
    • 6.2.1. Pituitary Tumors
    • 6.2.2. Meningioma
    • 6.2.3. Glioblastoma
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacy
    • 6.3.2. Retail & Online Pharmacy
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
      • 6.4.1.1. By Indication
    • 6.4.2. Canada
      • 6.4.2.1. By Indication

7. Europe Brain Tumor Drugs Market Analysis, Insights and Forecast, 2025-2034

  • 7.1. Market Analysis, Insights and Forecast - By Therapy
    • 7.1.1. Targeted Therapy
    • 7.1.2. Chemotherapy
    • 7.1.3. Immunotherapy
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Indication
    • 7.2.1. Pituitary Tumors
    • 7.2.2. Meningioma
    • 7.2.3. Glioblastoma
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacy
    • 7.3.2. Retail & Online Pharmacy
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.4.1. Germany
      • 7.4.1.1. By Indication
    • 7.4.2. U.K.
      • 7.4.2.1. By Indication
    • 7.4.3. France
      • 7.4.3.1. By Indication
    • 7.4.4. Spain
      • 7.4.4.1. By Indication
    • 7.4.5. Italy
      • 7.4.5.1. By Indication
    • 7.4.6. Scandinavia
      • 7.4.6.1. By Indication
    • 7.4.7. Rest of Europe
      • 7.4.7.1. By Indication

8. Asia Pacific Brain Tumor Drugs Market Analysis, Insights and Forecast, 2025-2034

  • 8.1. Market Analysis, Insights and Forecast - By Therapy
    • 8.1.1. Targeted Therapy
    • 8.1.2. Chemotherapy
    • 8.1.3. Immunotherapy
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Indication
    • 8.2.1. Pituitary Tumors
    • 8.2.2. Meningioma
    • 8.2.3. Glioblastoma
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacy
    • 8.3.2. Retail & Online Pharmacy
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.4.1. Japan
      • 8.4.1.1. By Indication
    • 8.4.2. China
      • 8.4.2.1. By Indication
    • 8.4.3. India
      • 8.4.3.1. By Indication
    • 8.4.4. Australia
      • 8.4.4.1. By Indication
    • 8.4.5. Southeast Asia
      • 8.4.5.1. By Indication
    • 8.4.6. Rest of Asia Pacific
      • 8.4.6.1. By Indication

9. Latin America Brain Tumor Drugs Market Analysis, Insights and Forecast, 2025-2034

  • 9.1. Market Analysis, Insights and Forecast - By Therapy
    • 9.1.1. Targeted Therapy
    • 9.1.2. Chemotherapy
    • 9.1.3. Immunotherapy
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Indication
    • 9.2.1. Pituitary Tumors
    • 9.2.2. Meningioma
    • 9.2.3. Glioblastoma
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacy
    • 9.3.2. Retail & Online Pharmacy
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.4.1. Brazil
      • 9.4.1.1. By Indication
    • 9.4.2. Mexico
      • 9.4.2.1. By Indication
    • 9.4.3. Rest of Latin America
      • 9.4.3.1. By Indication

10. Middle East & Africa Brain Tumor Drugs Market Analysis, Insights and Forecast, 2025-2034

  • 10.1. Market Analysis, Insights and Forecast - By Therapy
    • 10.1.1. Targeted Therapy
    • 10.1.2. Chemotherapy
    • 10.1.3. Immunotherapy
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Indication
    • 10.2.1. Pituitary Tumors
    • 10.2.2. Meningioma
    • 10.2.3. Glioblastoma
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital Pharmacy
    • 10.3.2. Retail & Online Pharmacy
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.4.1. GCC
      • 10.4.1.1. By Indication
    • 10.4.2. South Africa
      • 10.4.2.1. By Indication
    • 10.4.3. Rest of Middle East & Africa
      • 10.4.3.1. By Indication

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Product, SWOT Analysis, Recent Developments, Strategies, financials (Based on Availability))
    • 11.2.1. Pfizer Inc.
      • 11.2.1.1. Overview,
      • 11.2.1.2. Product,
      • 11.2.1.3. SWOT Analysis,
      • 11.2.1.4. Recent Developments,
      • 11.2.1.5. Strategies,
      • 11.2.1.6. financials (Based on Availability)
    • 11.2.2. F. Hoffmann-La Roche Ltd
      • 11.2.2.1. Overview,
      • 11.2.2.2. Product,
      • 11.2.2.3. SWOT Analysis,
      • 11.2.2.4. Recent Developments,
      • 11.2.2.5. Strategies,
      • 11.2.2.6. financials (Based on Availability)
    • 11.2.3. Novartis AG
      • 11.2.3.1. Overview,
      • 11.2.3.2. Product,
      • 11.2.3.3. SWOT Analysis,
      • 11.2.3.4. Recent Developments,
      • 11.2.3.5. Strategies,
      • 11.2.3.6. financials (Based on Availability)
    • 11.2.4. Merck & Co. Inc.
      • 11.2.4.1. Overview,
      • 11.2.4.2. Product,
      • 11.2.4.3. SWOT Analysis,
      • 11.2.4.4. Recent Developments,
      • 11.2.4.5. Strategies,
      • 11.2.4.6. financials (Based on Availability)
    • 11.2.5. Amneal Pharmaceuticals LLC.
      • 11.2.5.1. Overview,
      • 11.2.5.2. Product,
      • 11.2.5.3. SWOT Analysis,
      • 11.2.5.4. Recent Developments,
      • 11.2.5.5. Strategies,
      • 11.2.5.6. financials (Based on Availability)
    • 11.2.6. Amgen Inc.
      • 11.2.6.1. Overview,
      • 11.2.6.2. Product,
      • 11.2.6.3. SWOT Analysis,
      • 11.2.6.4. Recent Developments,
      • 11.2.6.5. Strategies,
      • 11.2.6.6. financials (Based on Availability)
    • 11.2.7. NextSource Pharmaceuticals, LLC
      • 11.2.7.1. Overview,
      • 11.2.7.2. Product,
      • 11.2.7.3. SWOT Analysis,
      • 11.2.7.4. Recent Developments,
      • 11.2.7.5. Strategies,
      • 11.2.7.6. financials (Based on Availability)
    • 11.2.8. Emcure Pharmaceuticals
      • 11.2.8.1. Overview,
      • 11.2.8.2. Product,
      • 11.2.8.3. SWOT Analysis,
      • 11.2.8.4. Recent Developments,
      • 11.2.8.5. Strategies,
      • 11.2.8.6. financials (Based on Availability)

List of Tables

  • Table 1: Global Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Therapy, 2025-2034
  • Table 2: Global Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 3: Global Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
  • Table 4: Global Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Region, 2025-2034
  • Table 5: North America Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Therapy, 2025-2034
  • Table 6: North America Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 7: North America Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
  • Table 8: North America Brain Tumor Drugs Market Revenue (USD billion) Forecast, By Country, 2025-2034
  • Table 9: U.S. Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 10: Canada Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 11: Europe Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Therapy, 2025-2034
  • Table 12: Europe Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 13: Europe Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
  • Table 14: Europe Brain Tumor Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2025-2034
  • Table 15: Germany Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 16: U.K. Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 17: France Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 18: Italy Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 19: Spain Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 20: Scandinavia Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 21: Rest of Europe Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 22: Asia Pacific Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Therapy, 2025-2034
  • Table 23: Asia Pacific Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 24: Asia Pacific Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
  • Table 25: Asia Pacific Brain Tumor Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2025-2034
  • Table 26: Japan Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 27: India Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 28: China Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 29: Australia Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 30: Southeast Asia Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 31: Rest of Asia Pacific Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 32: Latin America Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Therapy, 2025-2034
  • Table 33: Latin America Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 34: Latin America Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
  • Table 35: Latin America Brain Tumor Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2025-2034
  • Table 36: Brazil Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 37: Mexico Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 38: Rest of Latin America Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 39: Middle East & Africa Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Therapy, 2025-2034
  • Table 40: Middle East & Africa Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 41: Middle East & Africa Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
  • Table 42: Middle East & Africa Brain Tumor Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2025-2034
  • Table 43: GCC Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 44: South Africa Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 45: Rest of Middle East & Africa Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034

List of Figures

  • Figure 1: Global Brain Tumor Drugs Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Brain Tumor Drugs Market Value Share (%), by Therapy, 2025 & 2034
  • Figure 3: Global Brain Tumor Drugs Market Forecast (USD billion), by Targeted Therapy, 2025-2034
  • Figure 4: Global Brain Tumor Drugs Market Forecast (USD billion), by Chemotherapy, 2025-2034
  • Figure 5: Global Brain Tumor Drugs Market Forecast (USD billion), by Immunotherapy, 2025-2034
  • Figure 6: Global Brain Tumor Drugs Market Forecast (USD billion), by Others, 2025-2034
  • Figure 7: Global Brain Tumor Drugs Market Value Share (%), by Indication, 2025 & 2034
  • Figure 8: Global Brain Tumor Drugs Market Forecast (USD billion), by Pituitary Tumors, 2025-2034
  • Figure 9: Global Brain Tumor Drugs Market Forecast (USD billion), by Meningioma, 2025-2034
  • Figure 10: Global Brain Tumor Drugs Market Forecast (USD billion), by Glioblastoma, 2025-2034
  • Figure 11: Global Brain Tumor Drugs Market Forecast (USD billion), by Others, 2025-2034
  • Figure 12: Global Brain Tumor Drugs Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 13: Global Brain Tumor Drugs Market Forecast (USD billion), by Hospital Pharmacy, 2025-2034
  • Figure 14: Global Brain Tumor Drugs Market Forecast (USD billion), by Retail & Online Pharmacy, 2025-2034
  • Figure 15: Global Brain Tumor Drugs Market Value (USD billion), by Region, 2025 & 2034
  • Figure 16: North America Brain Tumor Drugs Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 17: North America Brain Tumor Drugs Market Value Share (%), by Therapy, 2025
  • Figure 18: North America Brain Tumor Drugs Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 19: North America Brain Tumor Drugs Market Value Share (%), by Indication, 2025
  • Figure 20: North America Brain Tumor Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 21: North America Brain Tumor Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 22: North America Brain Tumor Drugs Market Value (USD billion), By Country, 2025 & 2034
  • Figure 23: North America Brain Tumor Drugs Market Value Share (%), By Country, 2025
  • Figure 24: Europe Brain Tumor Drugs Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 25: Europe Brain Tumor Drugs Market Value Share (%), by Therapy, 2025
  • Figure 26: Europe Brain Tumor Drugs Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 27: Europe Brain Tumor Drugs Market Value Share (%), by Indication, 2025
  • Figure 28: Europe Brain Tumor Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 29: Europe Brain Tumor Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 30: Europe Brain Tumor Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe Brain Tumor Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 32: Asia Pacific Brain Tumor Drugs Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 33: Asia Pacific Brain Tumor Drugs Market Value Share (%), by Therapy, 2025
  • Figure 34: Asia Pacific Brain Tumor Drugs Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 35: Asia Pacific Brain Tumor Drugs Market Value Share (%), by Indication, 2025
  • Figure 36: Asia Pacific Brain Tumor Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 37: Asia Pacific Brain Tumor Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 38: Asia Pacific Brain Tumor Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 39: Asia Pacific Brain Tumor Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 40: Latin America Brain Tumor Drugs Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 41: Latin America Brain Tumor Drugs Market Value Share (%), by Therapy, 2025
  • Figure 42: Latin America Brain Tumor Drugs Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 43: Latin America Brain Tumor Drugs Market Value Share (%), by Indication, 2025
  • Figure 44: Latin America Brain Tumor Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 45: Latin America Brain Tumor Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 46: Latin America Brain Tumor Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 47: Latin America Brain Tumor Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 48: Middle East & Africa Brain Tumor Drugs Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 49: Middle East & Africa Brain Tumor Drugs Market Value Share (%), by Therapy, 2025
  • Figure 50: Middle East & Africa Brain Tumor Drugs Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 51: Middle East & Africa Brain Tumor Drugs Market Value Share (%), by Indication, 2025
  • Figure 52: Middle East & Africa Brain Tumor Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 53: Middle East & Africa Brain Tumor Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 54: Middle East & Africa Brain Tumor Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 55: Middle East & Africa Brain Tumor Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 56: Global Brain Tumor Drugs Market Share (%), By Company, 2025